NCT07540949Recruiting
Rutazyme Lemon Fermented Product Capsules for Metabolic Function in Adults With Obesity
Evaluation of Metabolic Functionality of Fruit and Vegetable Fermented Products in Adults
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
This study evaluates whether a fruit- and vegetable-based fermented product (Rutazyme® lemon fermented product) taken as a capsule can improve metabolic health in adults with obesity. Forty adults aged 18-65 years with obesity (BMI ≥ 27 kg/m² and waist circumference \> 90 cm for men or \> 80 cm for women) will be randomly assigned to receive either a Rutazyme® lemon fermented product capsule (500 mg) or a placebo capsule once daily at bedtime for 12 weeks. Before supplementation, participants will complete a 2-week stabilization period during which they maintain their usual diet and physical activity. Body composition and waist/hip measurements will be assessed during the study, and blood pressure will be monitored. Blood samples will be collected to evaluate metabolic and safety laboratory measures (e.g., lipids, glucose, insulin, inflammation markers, liver and kidney function), and stool samples will be collected to assess gut microbiota. Gut-brain axis biomarkers (GLP-1 and PYY) will be measured at multiple time points after capsule intake at baseline and at Week 12. The results will help determine the metabolic effects and safety of Rutazyme® lemon fermented product supplementation in adults with obesity.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 12 Apr 2026
- Start date
- 16 Mar 2026
- Primary completion date
- 31 May 2026
- Lead sponsor
- National Taiwan Sport University
- Diseases
- Obesity
- NCT number
- NCT07540949
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 16 Mar 2026 to the primary completion date, 31 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current treatment with antihypertensive medications.
Other illness
- Gastrointestinal disorders, including inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease).
- Major cardiovascular, metabolic, or renal disease.
Other
- Pregnant, breastfeeding, or menopausal or postmenopausal.
- Use of enzyme supplements or fiber supplements within the past month.
- Unable to provide informed consent or insufficient decision-making capacity.
- Investigator determines the participant is not suitable for the study.
Who the study is looking for
- Age 18 to 65 years.
- Body mass index (BMI) ≥ 27 kg/m².
- Waist circumference \> 90 cm for men or \> 80 cm for women.
- Able and willing to provide written informed consent and comply with study procedures.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Taiwan Sport University Coordinator of this site? Confirm its status | Taoyuan | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.